Crash Course in Cures: Hypomethylating Agent & Venetoclax Combination in Newly Diagnosed Older Adults
Being Newly Diagnosed opens a whole world of treatment plans. Join HealthTree as we hear from Dr.Swoboda on how hypomethylating agent & Venetoclax work together to treat Older Newly Diagnosed Leukemia patients. There will be a Q&A session at the end so come with questions!
Eliza introduces the agenda of the event and our featured speaker Dr. David Swoboda
Dr.Swoboda explains how hypomethylating agent & Venetoclax work together to treat Older Newly Diagnosed Leukemia patients.
Come with your questions and we'll answer them!
Eliza Prickett
Eliza joined HealthTree in March 2026 as the Leukemia Patient Health Education Manager. Prior to joining HealthTree, she completed a Master’s Degree in Public Health from Brigham Young University and worked with a variety of underserved populations in government and healthcare settings, including Americorps and Utah Health Department. When not in office, Eliza enjoys reading, writing and learning new things about the world.
David Swoboda, MD
David Swoboda, M.D. is a member of the Hematologic Malignancies Program at Tampa General Hospital Cancer Institute and Assistant Professor at the University of South Florida College of Medicine. Prior to joining TGH, Dr. Swoboda served as the chief hematology/oncology fellow at Moffitt Cancer Center and chief resident at Georgetown University Hospital He is actively involved in the care of patients with acute leukemias and myelodysplastic syndromes (MDS) in addition to serving as principal investigator on multiple clinical trials in these diseases. Dr. Swoboda’s research focuses on the genetic drivers and inflammatory significant of myeloid malignancies. He has presented his work at numerous national conferences and has several first author publications in top-tier journals including Leukemia and American Journal of Hematology.